As you probably know, shark cartilage projects have been around for a long time. Bioimmune once had a project that sounded exactly like AEOL's...... did AEOL get it from Bioimmune, or were they seperate from the beginning? Patent position possible?
There are any number of molecules that are known to inhibit angiogenesis. Almost any polycation will do such, but they're also plagued by toxicity. They inhibit the binding of growth factors to heparan, and thus inhibit the presentation of the GFs necessary to interact with receptors (such as bFGF). One polycation is squalamine, with a sterol backbone and positively charged "side chains". I forget the new name of the company, but Magainin is developing squalamine as an anti-angiogenic, and it is isolated from sharks.
Boston Life Sciences also had an old project for a cartilage-derived angiogenesis inhibitor, and there were others. But I don't remember the "shark" component for anything apart from Bioimmune.
Companies where old projects may be of interest..... Repligen, Boston Life Sciences, Magainin (new name?), Bioimmune. Isn't there also an Australian company which is working with a polycation for angiogenesis?
edit: no, I remembered..... the aussie company is working with a heparanase.... same concept, even more difficult from a conceptual stance. |
